Company intelligence / Profile preview

Gotham

New York, NY, USA

Ownership: Private
Development stage: Other

Overview

Gotham Therapeutics was a biotechnology company pioneering the field of epitranscriptomics to develop novel small molecule drugs. The company focused on targeting RNA-modifying proteins that regulate the modification of RNA, a process critical to gene expression and cellular function. By leveraging its proprietary platform, Gotham aimed to treat a variety of diseases, including oncology, autoimmune, and neurodegenerative disorders. In 2021, the company was acquired by and merged into 858 Therapeutics to combine their efforts in the RNA-modifying protein space.

Therapeutic areas: OncologyImmunologyNeurology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Gotham.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Gotham.

Explore the full profile